Government to pay nearly half of health costs within a decade

Share this article:
Federal analysts forecasted that federal, state and local governments will be paying approximately half of U.S. health costs by 2014 -- a shift largely reflected by the new Medicare prescription drug benefit, a Wall Street Journal report today said.
The government will pay 49 percent of health costs by 2014, up from current Medicare estimates of 46 percent.
An estimated $67 billion in drug spending will shift to Medicare from private insurers and Medicaid when the Medicare drug benefit begins in 2006.
"The public sector will feel more deeply the financial burden associated with supplying healthcare benefits to Medicare and Medicaid enrollees," federal analysts wrote in an article published by the journal Health Affairs.
States will pay a portion of the drug costs incurred by beneficiaries eligible for both programs and the federal government will pick up the tab as more Medicare beneficiaries, who have been paying out of pocket for their prescription drugs, sign up for the new benefit.
The Medicare drug benefit is predicted to create an initial rise in prescription drug use by Medicare beneficiaries and a minor rise in spending on medications.
In the drug benefit's first year, total spending on prescriptions is expected to grow nearly 12 percent. Drug price growth, including the Medicare drug benefit, will account for 2.4 percentage points of the surge, the Wall Street Journal report said.
 
Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.